{"page":{"totalFilteredElements":11},"studies":[{"active":true,"description":" A Phase 3, Randomized, Open Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants with relapesd, refractory Multiple Myeloma (KT-US-679-0788, iMMagine-3)","eudractNumber":"2024-511188-26","id":9859,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT06413498","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-06-13T10:01:57+02:00","shortTitle":"iMMagine-3","therapeutical":true,"therapyLines":[{"id":"tl_8","name":"Advanced"}]}]}